gms | German Medical Science

57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

11. bis 14.05.2006, Essen

NCAM-140 is down-regulated in human gliomas with increasing WHO grade – final results

NCAM-140 sinkt mit steigenden WHO-Grad in humanen Gliomen – finale Ergebnisse

Meeting Abstract

  • corresponding author S.A. Kuhn - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • K. Ebmeier - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • R. Reichart - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • M. Brodhun - Klinik für Pathologie, Klinikum der Friedrich-Schiller-Universität Jena
  • C. Ewald - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • P. Dünisch - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • J. Koblitz - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • R. Kalff - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie. Essen, 11.-14.05.2006. Düsseldorf, Köln: German Medical Science; 2006. DocP 05.59

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2006/06dgnc276.shtml

Veröffentlicht: 8. Mai 2006

© 2006 Kuhn et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Gliomas interact with their microenvironment. NCAM-140 is one of the best known interaction molecules. It is expressed in neurons and glia, but also in gliomas. We want to investigate NCAM-140-expression in human gliomas.

Methods: Staining was performed on sections of 171 human gliomas and 39 other intracranial tumors with polyclonal antibodies to NCAM-140. Morphology was characterized by hematoxylin/eosin. Autopsy material of 20 patients served as control. Densitometry was done with Image 1.41 for Mac computers. SPSS version 13.0 was used for statistics.

Results: With the first statistically evaluated 92 tumors, we confirmed our recent results that have shown a down-regulation of NCAM-140 expression in human gliomas of different histology with increasing tumor grade according to WHO. Initial macroscopy and microscopy enabled visualization of major differences of NCAM-140-expression status. This was confirmed by densitometry. Mean density of NCAM-140 immunoreactivity was 152.44 (±5.12) in control brain tissue and was significantly different from all other glioma entities. Mean densities of 144.01 (±4.82) in low-grade glioma and 142.57 (±6.07) in anaplastic glioma were significantly different from each other, and were different from mean density of NCAM-140 immunoreactivity in glioblastomas of 140.51 (±2.62) with statistical significance. Mixed gliomas overtake an intermediate position with respect to their NCAM-140-positivity. Four glioblastomas out of 22 expressed unusual high amounts of NCAM-140 that can be compared with healthy brain tissue. Whether this is related to a better outcome remains to be investigated. Optic density of NCAM-140-expression in other intracranial tumors was significantly different from that of gliomas.

Conclusions: The NCAM-140-expression is inversely correlated to WHO grade in human gliomas, with the glioblastomas demonstrating negativity in the very most cases. The expression profile of NCAM-140 was typical only for gliomas and differed strictly from that of other intracranial tumors. Further studies are mandatory to correlate the NCAM-140 expression profile with the prognosis data of patients and are on the way.